Skip to main content

A second open letter to NIH for revisions to CCP recommendations

11 Comments

M
Melissa Edwards
Featured

Please help give immunocompromised individuals all the options we can get to fight COVID.

R
Rita A Reik MD FCAP
Featured

It is critical that clinicians remain aware of very high-titer COVID-19 convalescent plasma as an FDA-authorized therapy. It offers an advantage over pharmaceuticals in that it is produced real time and reflects the most recent variants circulating in the population.

D
Daniel F Hanley
Featured

Legum Professor Acute Care Neurology, Director Multisite Clinical Trials Johns Hopkins ICTR

B
Barry Meisenberg MD

We will likely need this tool

B
Brian Koffman MDCM MS Ed
Featured

Brian Koffman MDCM (retired) MS Ed Co-Founder, Executive VP and Chief Medical Officer CLL Society, Inc.

M
Mei Chang
Featured

Please help increase access to important therapeutic options, particularly for our immunocompromised population.

M
MarieElena Cordisco MA NPC APRN

This is an important and lifesaving therapy

J
Johanna Patricia Daily

CCP would provide us an option for our patients who are immunocompromised.

J
Josh Nosanchuk

This is a life-saving therapy!

W
Walter Ian Lipkin
Featured

John Snow Professor of Epidemiology Mailman School of Public Health Columbia University

D
Dan Cruser MD

Thx.